MA39101A1 - Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins - Google Patents

Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins

Info

Publication number
MA39101A1
MA39101A1 MA39101A MA39101A MA39101A1 MA 39101 A1 MA39101 A1 MA 39101A1 MA 39101 A MA39101 A MA 39101A MA 39101 A MA39101 A MA 39101A MA 39101 A1 MA39101 A1 MA 39101A1
Authority
MA
Morocco
Prior art keywords
kidney diseases
drugs against
adenosine agonists
diseases
agonists used
Prior art date
Application number
MA39101A
Other languages
English (en)
Inventor
Alexandros Vakalopoulos
Katja Zimmermann
Barbara Albrecht-Küpper
Kirsten Leineweber
Axel Kretschmer
Daniel Meibom
Nicole Diedrichs
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49759125&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA39101A1 publication Critical patent/MA39101A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne des agonistes sélectifs partiaux du récepteur a1 de l'adénosine de la formule (i) et leur utilisation pour le traitement et/ou la prévention de maladies, ainsi que leur utilisation pour la production de médicaments utilisés pour le traitement et/ou la prévention de maladies, de préférence pour le traitement et/ou la prévention de maladies aigües et/ou chroniques des reins (maladie primaire et maladie secondaire) s'accompagnant ou non de maladies aigües ou et/ou chroniques du cœur.
MA39101A 2013-12-12 2014-12-09 Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins MA39101A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13196780 2013-12-12
PCT/EP2014/076978 WO2015086561A1 (fr) 2013-12-12 2014-12-09 Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins

Publications (1)

Publication Number Publication Date
MA39101A1 true MA39101A1 (fr) 2017-08-31

Family

ID=49759125

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39101A MA39101A1 (fr) 2013-12-12 2014-12-09 Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins

Country Status (21)

Country Link
US (1) US20160311812A1 (fr)
EP (1) EP3079696A1 (fr)
JP (1) JP2016539986A (fr)
KR (1) KR20160094974A (fr)
CN (1) CN105792826A (fr)
AP (1) AP2016009245A0 (fr)
AU (1) AU2014363705A1 (fr)
CA (1) CA2933244A1 (fr)
CL (1) CL2016001357A1 (fr)
EA (1) EA201691218A1 (fr)
IL (1) IL245866A0 (fr)
MA (1) MA39101A1 (fr)
MX (1) MX2016007343A (fr)
MY (1) MY174230A (fr)
PH (1) PH12016501127A1 (fr)
SG (1) SG11201604414PA (fr)
SV (1) SV2016005210A (fr)
TN (1) TN2016000233A1 (fr)
UA (1) UA117771C2 (fr)
WO (1) WO2015086561A1 (fr)
ZA (1) ZA201603465B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019082912A1 (fr) * 2017-10-27 2019-05-02 学校法人北里研究所 Agent prophylactique ou thérapeutique contre une néphropathie chronique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE102007036075A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Ag Prodrugs und ihre Verwendung
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension

Also Published As

Publication number Publication date
CN105792826A (zh) 2016-07-20
SV2016005210A (es) 2017-08-08
UA117771C2 (uk) 2018-09-25
CA2933244A1 (fr) 2015-06-18
AP2016009245A0 (en) 2016-05-31
EA201691218A1 (ru) 2016-11-30
SG11201604414PA (en) 2016-07-28
TN2016000233A1 (en) 2017-10-06
PH12016501127A1 (en) 2016-07-18
EP3079696A1 (fr) 2016-10-19
MY174230A (en) 2020-04-01
US20160311812A1 (en) 2016-10-27
MX2016007343A (es) 2016-09-13
ZA201603465B (en) 2019-07-31
AU2014363705A1 (en) 2016-06-30
CL2016001357A1 (es) 2017-01-13
IL245866A0 (en) 2016-07-31
KR20160094974A (ko) 2016-08-10
WO2015086561A1 (fr) 2015-06-18
JP2016539986A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
EA201792047A1 (ru) Новые соединения
PH12015502658A1 (en) 3,4-dihydroisoquinolin-2 (1h)-yl compounds
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
MA38925A1 (fr) Dérivés de phénylalanine substitués
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
PH12015501793A1 (en) Bicyclic compounds
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
MA43250B1 (fr) Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues
EA201691788A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
MA38654B1 (fr) Dérivés de type promédicament de triazolopyridines substituées
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39101A1 (fr) Agonistes a1 de l'adénosine utilisés comme médicaments contre les maladies des reins
EA201500232A1 (ru) Три(гетеро)арилпиразолы и их применение
WO2017095918A3 (fr) Procédés de traitement du cancer au moyen d'antagonistes de rspo3
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA35938B1 (fr) Nouvelles combinaisons pour le traitement de la leucemie myeloide aigue ou de la leucemie myeloide chronique
MA33938B1 (fr) 5-alcynyl-pyrimidines
MA44836A (fr) Procédés de traitement du syndrome polykystique des reins
MA35894B1 (fr) Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k
MA43263B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA44144A (fr) Composés hétérocycliques utilisés comme immunomodulateurs